IMMX

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing oncology therapies targeting tissue factor and tissue factor pathway inhibitor (TFPI). The company's lead program focuses on treating solid tumors and hematological malignancies through novel mechanisms of action. Immix is advancing multiple candidates through preclinical and clinical development stages. The company's approach aims to address cancers with significant unmet medical needs through innovative targeting of the tissue factor pathway.